• Explore /
  • Poster
  • / A phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3).

A phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3).

Abstract Video & Slides Poster

Authors

Mehmet Akce

Mehmet Akce

Winship Cancer Institute, Atlanta, GA

Mehmet Akce , Siwen Hu-Lieskovan , Matthew Reilley , James Fredric Strauss , Jennifer M. Specht , Mark N. Stein , Judy S. Wang , Jennifer Hsing Choe , Rom Leidner , Diwakar Davar , Gerald Steven Falchook , Shubham Pant , Ezra E.W. Cohen , Breelyn A. Wilky , Benjamin Thompson , Raphael Clynes , Lingling Li , Patricia McGovern , David Neal Liebowitz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

PD1/PD-L1 Inhibitor Combinations

Clinical Trial Registration Number

NCT03752398

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 2604)

DOI

10.1200/JCO.2022.40.16_suppl.2604

Abstract #

2604

Poster Bd #

259

Abstract Disclosures

Similar Posters

First Author: Yufei Liu

First Author: Gerald Steven Falchook

First Author: Jermaine Coward

First Author: Alain Patrick Algazi